Tibsovo Tablets 250 mg General Drug Use-Results Survey (IDH1-mutated acute myeloid leukaemia)

Tibsovo Tablets 250 mg General Drug Use-Results Survey (IDH1-mutated acute myeloid leukaemia) - Tibsovo Tablets General Drug Use-Results Survey (IDH1-mutated acute myeloid leukaemia)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058014

Enrollment

268

Registered

2025-06-02

Start date

2025-06-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IDH1-mutated acute myeloid leukaemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with IDH1-mutated acute myeloid leukaemia who received this drug for the first time during the study period and agreed to participate in this study.

Exclusion criteria

Exclusion criteria: No given consent to participation in the survey.

Design outcomes

Primary

Measure	Time frame
Incidence of the side effect of Guillain-Barre syndrome	—

Secondary

Measure	Time frame
Efficacy and safety in patients with IDH1-mutated AML	—

Countries

Japan

Contacts

Public ContactDaisuke Tanaka

NIHON SERVIER CO., LTD. DRUG SAFETY & REAL WORLD EVIDENCE

daisuke.tanaka@servier.com07075969589

Outcome results